HIV-1 infection kinetics, drug resistance, and long-term safety of pre-exposure prophylaxis with emtricitabine plus tenofovir alafenamide (DISCOVER): week 144 open-label extension of a randomised, controlled, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet HIV

Topics

Medicine

Internal Medicine

Infectious Diseases

Virology

Tenofovir

Show all topics

DOI

10.1016/s2352-3018(24)00130-9